Findings
Clearly defining the Context of Use (CoU) is essential for regulatory assessment and qualification success.
Qualification requires robust diagnostic and prognostic performance, including sensitivity, specificity, and predictive values.
Statistical analysis plans (SAPs) must be pre-specified and justify the inclusion of exploratory and confirmatory data sets.
Clinical utility should be demonstrated by showing the methodology’s impact on diagnostic thinking, patient management, and outcomes.
Validation of the analytical platform for its intended Context of Use is critical to ensure reliability and robustness.

Recommendations
Define the Context of Use (CoU) with clarity, specifying how the novel methodology will be applied and its purpose in drug development.
Validate the analytical platform and demonstrate its robustness for the intended application.
Ensure statistical planning aligns with regulatory expectations, with pre-specified analysis plans and justification for exploratory and confirmatory approaches.
Establish clinical utility by detailing the methodology’s impact on patient management and clinical outcomes.
Address limitations to the standard of truth with appropriate surrogate standards, where necessary, ensuring they are well-justified.

Regulatory Considerations
Follow ICH guidelines, including ICH E16 (genomic biomarkers), ICH E18 (sampling and data management), and ICH E9 (statistical principles for clinical trials), for data structure and validation.
Use reflection papers on pharmacogenomic samples and data handling for guidance on sample storage, transport, and testing.
Ensure compliance with regulatory requirements for analytical and performance validation, as specified in EMA guidance documents.
Leverage cross-validation methods, especially in rare disease scenarios, with pre-specified methodologies.